INVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLC

Core Points - Unicycive Therapeutics, Inc. announced that the U.S. FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for OLC, intended to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis [1] - Following the FDA's announcement, Unicycive's stock price experienced a decline [1] Company Overview - Holzer & Holzer, LLC is investigating whether Unicycive complied with federal securities laws in light of the recent FDA decision [1] - The law firm specializes in representing shareholders and investors in litigation, including shareholder class action and derivative litigation [3] - Holzer & Holzer has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]